Nghiên cứu đặc điểm lâm sàng, hình ảnh nội soi và hiệu quả điều trị của phác đồ 4 thuốc có Bismuth trên bệnh nhân viêm loét dạ dày tá tràng do nhiễm Helicobacter pylori tại Bệnh viện trường đại học Y Dược Cần Thơ

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Hiếu Tâm Huỳnh, Thị Hồng Nhung Thái

Ngôn ngữ: vie

Ký hiệu phân loại: 616.33 *Diseases of stomach

Thông tin xuất bản: Tạp chí Y Dược học - Trường Đại học Y Dược Huế, 2020

Mô tả vật lý: 45485

Bộ sưu tập: Metadata

ID: 494268

Thêm vào giỏ

Mô tả đặc điểm lâm sàng và hình ảnh nội soi của bệnh nhân viêm loét dạ dày tá tràng có nhiễm Helicobacter pylori. Đánh giá hiệu quả điều trị của phác đồ 4 thuốc có Bismuth trong điều trị viêm loét dạ dày tá tràng do nhiễm Helicobacter pylori. Tất cả bệnh nhân được điều trị phác đồ 4 thuốc có Bismuth (RBTT) gồm Rapeprazole 20 mg x 2 lần/ngày
Colloidal Bismut Subcitrate 120mg x 4 lần/ ngày
Tetracydine 500mg x 4 lần/ngày và Tinidazol 500mg x 3 lần ngày trong 14 ngày. Chẩn đoán viêm loét dạ dày tá tràng có nhiễm Helicobacter pylori dựa vào nội soi tiêu hóa trên kèm xét nghiệm urease test nhanh. Trong vòng 4-8 tuần sau khi ngưng điều trị, tình trạng Helicobacter pylori được kiểm tra lại bằng thử nghiệm urease test nhanh (Clotest) hoặc C13 urea-breath. Kết quả: Triệu chứng lâm sàng thường gặp nhất của bệnh nhân trước điều trị là đau thượng vị (75%), tổn thương nội soi thường gặp nhất là viêm sung huyết (57,5%) và loét (12,5%). Tỷ lệ diệt trừ Helicobacter pylori của phác đồ bốn thuốc có Bismuth theo ý định điều trị (ITT) và thiết kế nghiên cứu (PP) lần lượt là 95% và 97,2%. Tác dụng phụ xảy ra ở 75% bệnh nhân. Các tác dụng phụ thường gặp là mệt mỏi, chán ăn và buồn nôn. Tỷ lệ tuân thủ của bệnh nhân là 97,5%. Kết luận: Phác đồ 4 thuốc có Bismuth có tỷ lệ tiệt trừ rất cao. Tác dụng phụ thường gặp nhưng không nghiêm trọng.The clinical characteristics, endoscopic findings and the efficacy of the Bismuth-containing quadruple regimen in treatment of patients with Helicobacter pylori gastroduodenal inflammatory and ulcer at Can Tho hospital of university of medicine and pharmacy Describe the clinical characteristics and endoscopic findings of patients with Helicobacter pylori gastroduodenal inflammatory and ulcer. Evaluate the efficacy of Bismuth-based therapy for the treatment of Helicobacter pylori infection. Patients and methods: From November 2019 to May 2020 we carried out our study on 40 patients with Helicobacter pylori infection. All of patients received a quadruple therapy consisted of Rapeprazole 20 mg bid, Colloidal bismuth subcitrate 120mg qid, Tetracycline 500mg qid and Tinidazol 500mg tid for 14 days. The diagnosis of Helicobacter pylori infection was performed by Clotest. Four to eight weeks after completion of therapy, Helicobacter pylori status was rechecked by Clotest or C13 urea-breath test. Results: A total of 40 patients with Helicobacter pylori infection were recruited. The most common clinical characteristics was epigastric pain (75%), the most popularly identified endoscopic findings were erythematous gastritis (57.5%) and ulcer (12.5%). The eradication rates of the Bismuth-containing quadruple regimen on intention to treat (ITT) and per-protocol (PP) analysis were 95% and 97.2%, respectively. Adverse effects occurred in 75% of subjects. The common side effects were fatigue, anorexia and nausea. The compliance rate was 97.5%.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR